Conclusions

In the INPULSIS trials in patients with IPF:
- The annual rate of decline in FVC in patients who received placebo appeared to be lower in patients who, at baseline, had a CPFE index-estimated extent of emphysema of ≥10% versus <10%.
- Nintedanib reduced the annual rate of decline in FVC both in patients with a CPFE index-estimated extent of emphysema <10% and ≥10% at baseline.